|Table of Contents|

Expression and clinical significance of VEGFR-3 mRNA in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2016 06
Page:
902-905
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of VEGFR-3 mRNA in breast cancer
Author(s):
Wang Huxia1; Wang Guanghui2; Zhu Jiang1; Song Zhangjun1; Han Pihua1; Yang Xiaomin1; Deng Zhiping1; Sheng Wei2
1.Breast Disease Center,Tumor Hospital of Shaanxi Province,Shaanxi Xi'an 710061,China;2.Department of General Surgery,the First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
breast cancer; VEGFR-3 mRNA; lymphatic metastasis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2016.06.016
Abstract:
Objective:To study the expression and clinical significance of VEGFR-3 mRNA in breast cancer.Methods:RT-PCR was adopted in detecting the VEGFR-3 mRNA expressions in 60 cases of breast cancer.Take 15 cases of breast fibroadenoma as control.Results:The positive ratio and degree of VEGFR-3 mRNA in breast cancer was higher than the control group.VEGFR-3 mRNA was conspicuously higher in lymph-node-positive group than in lymph-node-negative group.The expression of VEGFR-3 mRNA was positively correlated with axillary lymph node metastasis.There were no statistically significant differences in pathologic features,tumor size and clinical stage.Conclusion:The expression of VEGFR-3 mRNA was higher in breast cancer,and it played an important role in the lymph node metastasis.

References:

［1］Zhao YC,Ni XJ,Wang MH,et al.Tumor-derived VEGF-C,but not VEGF-D,promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients［J］.Med Oncol,2012,29(4):2594-2600.
［2］Iwami D,Brinkman CC,Bromberg JS.Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics［J］.Transplantation,2015,99(4):668-677.
［3］Raica M,Cimpean AM,Ceausu R,et al.Lymphatic microvessel density,VEGF-C,and VEGFR-3 expression in different molecular types of breast cancer［J］.Anticancer Res,2011,31(5):1757-1764.
［4］Albrecht I,Christofori G.Molecular mechanisms of lymphangiogenesis in development and cancer［J］.Int J Dev Biol,2011,55(4-5):483-494.
［5］Bruyere F,Noel A.Lymphangiogenesis:in vitro and in vivo models［J］.FASEB J,2010,24(1):8-21.
［6］Quagliata L,Klusmeier S,Cremers N,et al.Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model［J］.Clin Exp Metastasis,2014,31(3):351-365.
［7］Engelmann D,Mayoli-Nussle D,Mayrhofer C,et al.E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B［J］.J Mol Cell Biol,2013,5(6):391-403.
［8］Zarkada G,Heinolainen K,Makinen T,et al.VEGFR3 does not sustain retinal angiogenesis without VEGFR2［J］.Proc Natl Acad Sci USA,2015,112(3):761-766.
［9］Wu J,Chen L,Zhou W,et al.Expression of vascular endothelial growth factor receptor 3 in human breast cancer and its significance［J］.Chin J Reconstruct and Reconstruct Surg,2013,27(12):1487-1491.
［10］Deng Y,Zhang X,Simons M.Molecular controls of lymphatic VEGFR3 signaling［J］.Arterioscler Thromb Vasc Biol,2015,35(2):421-429.
［11］Bzowska M,Mezyk-Kopec R,Prochnicki T,et al.Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression［J］.Acta Biochim Pol,2013,60(3):263-275.
［12］Lee E,Koskimaki JE,Pandey NB,et al.Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A［J］.Neoplasia,2013,15(2):112-124.
［13］Chang YW,Su CM,Su YH,et al.Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects［J］.Oncotarget,2014,5(11):3823-3835.

Memo

Memo:
-
Last Update: 2016-01-29